Protagenic Therapeutics (PTIX)
Official siteBIOTECHNOLOGY
Last updated: Nov 13, 2026 at 4:00 PM ET
Protagenic Therapeutics (PTIX) Financials: Revenue, Profit and Cash Flow
Protagenic Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was $1.37M, operating cash flow was -$2.81M and free cash flow was -$2.81M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$667.19K.
Revenue and Margins
The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $4.50M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $0 | N/A | N/A | N/A | N/A |
| Dec 2025 | N/A | N/A | N/A | N/A | N/A |
| Mar 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Mar 2026, net income was positive. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Dec 2025 | Mar 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $37.72K | $1.02M | $0 | $0 | $0 | $0 | $0 | $0 | $347 |
| Gross profit | $0 | -$37.72K | -$1.02M | $0 | $0 | $0 | $0 | $0 | $0 | -$347 |
| Research and development | $901.90K | $1.70M | $376.74K | $3.94M | $3.32M | $1.59M | $1.14M | $699.80K | $807.95K | $881.19K |
| Operating income | -$4.50M | -$5.83M | -$2.59M | -$5.70M | -$4.53M | -$3.56M | -$4.14M | -$2.55M | -$2.09M | -$2.31M |
| Net income | $1.37M | -$5.16M | -$3.59M | -$5.53M | -$5.00M | -$3.56M | -$4.52M | -$2.55M | -$1.75M | -$2.56M |
| EBITDA | $5.60M | N/A | -$1.95M | -$5.52M | N/A | -$3.49M | -$3.63M | -$2.14M | -$1.74M | -$2.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$670.60K | -$961.25K | -$925.10K | -$1.11M | -$1.21M | -$1.45M | -$401.40K | -$355.37K | -$1.67M | -$1.74M | -$1.21M | -$1.43M |
| Net income | -$667.19K | -$963.62K | $2.21M | -$869.50K | -$5.06M | -$1.44M | -$850.29K | -$582.39K | -$1.61M | -$1.72M | -$1.68M | -$1.40M |
Balance Sheet
Annual
| Line item | Mar 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.65M | $2.13M | $1.96M | $4.32M | $8.04M | $11.06M | $879.25K | $842.27K | $696.88K | $1.78M |
| Current assets | $1.54M | $2.30M | $1.88M | $4.20M | $8.04M | $11.06M | $879.25K | $841.98K | $696.27K | $1.78M |
| Cash and equivalents | N/A | $2.21M | $1.84M | $1.29M | $215.19K | $541.17K | $671.09K | $798.62K | $362.49K | $399.69K |
| Total liabilities | $1.03M | $6.82M | $942.76K | $655.25K | $1.12M | $631.82K | $2.03M | $1.48M | $907.77K | $561.69K |
| Short-term debt | $0 | $3.16M | N/A | N/A | $344.23K | $0 | N/A | N/A | $0 | $0 |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $132.28K | $1.37M | $279.37K | $0 | $0 |
| Shareholder equity | $2.62M | -$4.69M | $1.01M | $3.67M | $6.92M | $9.94M | -$1.15M | -$634.37K | -$210.88K | $1.22M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.27M | $2.80M | $3.65M | $4.43M | $5.00M | $2.80M | $89.09K | $1.96M | $1.51M | $1.47M | $2.58M | $4.32M |
| Total liabilities | $1.15M | $1.07M | $1.03M | $6.82M | $9.70M | $1.07M | $5.04M | $942.76K | $789.32K | $674.56K | $446.10K | $655.25K |
| Cash and equivalents | $2.21M | $2.72M | N/A | $2.21M | $2.72M | $4.10M | $14.53K | $1.84M | $1.06M | $924.60K | $831.78K | $1.29M |
| Shareholder equity | $1.12M | $1.72M | $2.62M | -$2.39M | -$4.70M | $1.72M | -$4.95M | $1.01M | $719.01K | $792.52K | $2.13M | $3.67M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Dec 2025 | Mar 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.81M | -$4.14M | -$1.77M | -$4.22M | -$3.70M | -$1.99M | -$2.80M | -$1.35M | -$487.99K | -$1.07M |
| Capital expenditures | $3.30K | $3 | $0 | $0 | $149.78K | $1.80K | $0 | $0 | $0 | $0 |
| Free cash flow | -$2.81M | -$4.14M | -$1.77M | -$4.22M | -$3.85M | -$2.00M | -$2.80M | -$1.35M | -$487.99K | -$1.07M |
| Investing cash flow | $629.88K | $943.18K | $0 | $2.80M | $4.78M | $1.60M | -$9.91M | $0 | $250.00K | $1.05M |
| Financing cash flow | $3.87M | $4.51M | $1.81M | $1.96M | $0 | $0 | $12.58M | $1.22M | $670.00K | $670.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$488.89K | -$944.30K | $265.53K | -$509.67K | -$353.64K | -$1.75M | -$1.07M | -$353.64K | $504.15K | -$1.55M | -$1.66M | -$1.14M |
| Capital expenditures | N/A | N/A | N/A | $6 | $3 | $3 | $3 | $0 | $0 | $0 | $5 | $93.97K |
| Free cash flow | N/A | N/A | N/A | -$509.67K | -$353.64K | -$1.75M | -$1.07M | -$353.64K | $504.15K | -$1.55M | -$1.66M | -$1.24M |
Frequently Asked Questions About PTIX
What is Protagenic Therapeutics' annual revenue?
Protagenic Therapeutics reported revenue of $0 for the fiscal year ended Mar 31, 2026.
Is Protagenic Therapeutics profitable?
Yes. Protagenic Therapeutics reported net income of $1.37M for the fiscal year ended Mar 31, 2026.
How much free cash flow does PTIX generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$2.81M minus capital expenditures of $3.30K produced free cash flow of -$2.81M.
How much debt does Protagenic Therapeutics have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $0.
PTIX pages: Overview, Financials